The Effects of Glucagon on Hepatic Metabolism

Launched by ADRIAN VELLA · Aug 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how glucagon, a hormone that helps control blood sugar levels, affects the way the liver processes certain nutrients in people with obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Researchers want to understand if problems with how glucagon works in the body are linked to factors like obesity and liver fat, especially in people who are lean versus those who are overweight. The goal is to learn more about how glucagon influences liver metabolism, which could help in developing better treatments for these conditions.

If you are interested in participating, you should be between the ages of 18 and 75, be willing to take part, and be able to give consent. However, certain medical conditions—like having had previous upper abdominal surgery, active diseases, or issues that might affect MRI results—may exclude you from joining. Participants will undergo tests to see how glucagon affects their liver and metabolism, contributing to a better understanding of these conditions. This study is currently recruiting, and it's a chance to help advance medical knowledge while receiving thorough evaluations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing to participate
• • Able to give consent
• Exclusion Criteria:
• • History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
• • Active systemic illness or malignancy.
• • Symptomatic macrovascular or microvascular disease.
• • Contraindications to MRI (e.g. metal implants, claustrophobia).
• • Hematocrit \< 35%
• • TSH \< 0.4 or \> 5.5.
• • Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire